These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31478335)

  • 1. Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
    Cho YM; Deerochanawong C; Seekaew S; Suraamornkul S; Benjachareonwong S; Sattanon S; Chamnan P; Sirirak T; Kosachunhanun N; Pratipanawatr T; Suwanwalaikorn S; Lee WJ; Kim S; Choi S; Kang ES; Oh T; Kwon S; Lee MK
    Diabetes Obes Metab; 2020 Jan; 22(1):123-127. PubMed ID: 31478335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
    Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
    Han KA; Hwang YC; Moon SJ; Cho HC; Yoo HJ; Choi SH; Chon S; Kim KA; Kim TN; Kang JG; Park CY; Won JC; Cho E; Kim J; Park KS
    Diabetes Obes Metab; 2024 Sep; 26(9):3743-3752. PubMed ID: 38978173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
    Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH
    Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
    Jung CH; Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS;
    Diabetes Obes Metab; 2018 Jun; 20(6):1535-1541. PubMed ID: 29436761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).
    Lee BW; Min K; Hong EG; Ku BJ; Kang JG; Chon S; Lee WY; Park MK; Kim JH; Kim SY; Song K; Yoo SJ
    Endocrinol Metab (Seoul); 2023 Jun; 38(3):328-337. PubMed ID: 37408283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
    Kim SH; Lee SH; Yim HJ
    Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
    Bae JC; Min KW; Kim YH; Kim KA; Hong EG; Park CY; Han S; Cha BS
    Diabetes Obes Metab; 2019 Jan; 21(1):103-111. PubMed ID: 30084112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
    Dutta D; Agarwal A; Maisnam I; Singla R; Khandelwal D; Sharma M
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):374-387. PubMed ID: 33820392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 15. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.
    Yang SJ; Min KW; Gupta SK; Park JY; K Shivane V; Agarwal PK; Kim DM; Kim YE; Baik SH
    Diabetes Metab J; 2021 Jul; 45(4):606-612. PubMed ID: 33081425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
    Yoon SA; Han BG; Kim SG; Han SY; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang YH; Shin SH; Cha DR
    Diabetes Obes Metab; 2017 Apr; 19(4):590-598. PubMed ID: 28019072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
    Kim HJ; Noh JH; Moon MK; Choi SH; Ko SH; Rhee EJ; Hur KY; Jeong IK
    J Diabetes Res; 2024; 2024():8915591. PubMed ID: 38223523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
    Kwak SH; Hwang YC; Won JC; Bae JC; Kim HJ; Suh S; Lee EY; Lee S; Kim SY; Kim JH
    Diabetes Obes Metab; 2020 Feb; 22(2):173-181. PubMed ID: 31502749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.